Cover Image
市場調查報告書

後天性 (自體免疫性) 溶血性貧血:開發平台分析

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 200919
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
後天性 (自體免疫性) 溶血性貧血:開發平台分析 Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 60 Pages
簡介

所謂自體免疫性溶血性貧血(AIHA)是指由於外因性要素 (缺乏免疫力,醫藥品,感染疾病,紅血球的物理性損傷,暴露於毒素等) 所引起的溶血性貧血。主要的症狀有黃疸和暈眩,發熱,頭痛,貧血,發冷等。還有主要易罹病素質有年齡和性別,家族病史等。

本報告提供全球各國治療後天性 (自體免疫性) 溶血性貧血所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

後天性 (自體免疫性) 溶血性貧血概要

治療藥的開發

  • 後天性 (自體免疫性) 溶血性貧血開發中產品:概要
  • 後天性 (自體免疫性) 溶血性貧血開發中產品:比較分析

各企業正在開發的後天性 (自體免疫性) 溶血性貧血治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

後天性 (自體免疫性) 溶血性貧血治療藥:開發中的產品一覽 (各企業)

後天性 (自體免疫性) 溶血性貧血治療藥的開發企業

  • Agios Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Hansa Medical AB
  • Shire Plc

後天性 (自體免疫性) 溶血性貧血:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AG-348
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • C1 esterase inhibitor (human)
  • eculizumab
  • Endoglycosidase of Streptococcus pyogenes
  • TNT-003
  • TNT-009

後天性 (自體免疫性) 溶血性貧血治療藥:開發中產品的最新趨勢

後天性 (自體免疫性) 溶血性貧血治療藥:暫停中的計劃

後天性 (自體免疫性) 溶血性貧血的相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7151IDB

Summary

Global Markets Direct's, 'Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015', provides an overview of the Acquired (Autoimmune) Hemolytic Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acquired (Autoimmune) Hemolytic Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acquired (Autoimmune) Hemolytic Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acquired (Autoimmune) Hemolytic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acquired (Autoimmune) Hemolytic Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acquired (Autoimmune) Hemolytic Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Acquired (Autoimmune) Hemolytic Anemia Overview
  • Therapeutics Development
    • Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Overview
    • Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis
  • Acquired (Autoimmune) Hemolytic Anemia - Therapeutics under Development by Companies
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Acquired (Autoimmune) Hemolytic Anemia - Products under Development by Companies
  • Acquired (Autoimmune) Hemolytic Anemia - Companies Involved in Therapeutics Development
    • Agios Pharmaceuticals, Inc.
    • Alexion Pharmaceuticals, Inc.
    • Hansa Medical AB
    • Shire Plc
  • Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AG-348 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Endoglycosidase of Streptococcus pyogenes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNT-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNT-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acquired (Autoimmune) Hemolytic Anemia - Recent Pipeline Updates
  • Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects
  • Acquired (Autoimmune) Hemolytic Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2015: Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase Deficiency
      • May 21, 2015: Agios to Present Clinical and Preclinical Data On AG-348 at the 20th Congress of the European Hematology Association
      • Mar 24, 2015: Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency
      • Dec 08, 2014: Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
      • Nov 06, 2014: Agios Pharmaceuticals To Present Phase 1 Data On AG-348 At The 2014 American Society Of Hematology Annual Meeting
      • Oct 06, 2014: Agios Pharmaceuticals to Provides Update on AG-348 Webcast R&D Day on October 15, 2014
      • Jun 09, 2014: Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia
      • Apr 17, 2014: Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
      • Apr 14, 2014: True North Therapeutics Publishes Study in Blood Demonstrating Ex Vivo Efficacy of a C1s Antibody in Cold Agglutinin Disease Patient Samples
      • Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2015
  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Hansa Medical AB, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Shire Plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Recent Pipeline Updates, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2015
  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top